Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 78, Issue , 2017, Pages 34-50

  de Melo, Luiz Gustavo Piccoli ^a   Nunes, Sandra Odebrecht Vargas ^a   Anderson, George ^b   Vargas, Heber Odebrecht ^a   Barbosa, Décio Sabbattini ^a   Galecki, Piotr ^c   Carvalho, André F ^d   Maes, Michael ^a,e,f,g,h  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b CRC Scotland and London   (United Kingdom)

^c UNIVERSITY OF LODZ   (Poland)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f UNIVERSITY OF PLOVDIV   (Bulgaria)

^g Revitalis   (Netherlands)

^h DEAKIN UNIVERSITY   (Australia)

Author keywords

Bipolar disorders; Depressive disorders; Inflammation; Leaky gut; Metabolism; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ARYLDIALKYLPHOSPHATASE 1; CURCUMIN; CYTOKINE; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MINOCYCLINE; RESVERATROL; SIMVASTATIN; TOLL LIKE RECEPTOR; UBIDECARENONE; URIC ACID; ZINC;

ADIPOCYTE; ADJUVANT THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL TRANSLOCATION; BIPOLAR DISORDER; BODY MASS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DEPRESSION; DRUG MECHANISM; GOUT; HEART FAILURE; HUMAN; HYPERURICEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; MAJOR DEPRESSION; MANIA; METABOLIC SYNDROME X; METABOLISM; MOOD DISORDER; NITROSATIVE STRESS; NITROSYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PSORIATIC ARTHRITIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TRAUMATIC BRAIN INJURY; COMPLICATION;

BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; METABOLIC SYNDROME; NITROSATIVE STRESS; OXIDATIVE STRESS;

EID: 85019924499     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2017.04.027     Document Type: Review

References (309)

1. Aboul-Fotouh, S., Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol. Biochem. Behav. 104 (2013), 105–112.
2. Akhondzadeh, S., Milajerdi, M.R., Amini, H., Tehrani-Doost, M., Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 8:5 Pt 1 (2006), 485–489.
3. Albert, U., De Cori, D., Aguglia, A., Barbaro, F., Bogetto, F., Maina, G., Increased uric acid levels in bipolar disorder subjects during different phases of illness. J. Affect. Disord. 173 (2015), 170–175.
4. Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., Fruchart, J.C., James, W.P., Loria, C.M., Smith, S.C. Jr., International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:16 (2009), 1640–1645.
5. Alberti, K.G., Zimmet, P., Shaw, J., Group, I.D.F.E.T.F.C., The metabolic syndrome–a new worldwide definition. Lancet 366:9491 (2005), 1059–1062.
6. Aldini, G., Dalle-Donne, I., Facino, R.M., Milzani, A., Milzani, A., Carini, M., Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev. 27:6 (2007), 817–868.
7. Anderson, G., Maes, M., Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr. Pharm. Des. 20:23 (2014), 3812–3847.
8. Anderson, G., Jacob, A., Bellivier, F., Geoffroy, P.A., Bipolar disorder: the role of the kynurenine and melatonergic pathways. Curr. Pharm. Des. 22:8 (2016), 987–1012.
9. Anderson, G., Kubera, M., Duda, W., Lason, W., Berk, M., Maes, M., Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol. Rep. 65:6 (2013), 1647–1654.
10. Anderson, G., Maes, M., Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. 2015 (1535-1645 (Electronic)).
11. Anderson, G., Maes, M., The gut–brain axis: the role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions. Adv. Integr. Med. 2:1 (2015), 31–37.
12. Anderson, G., R.M., Maes, M., Multiple sclerosis: the role of increased gut permeability. Curr. Pharm. Des., 2017 (in press).
13. Anderson, G., S.M., Carvalho, A., Berk, M., Maes, M., Gut permeability and Parkinson's disease. Curr. Pharm. Des., 2017 (in press).
14. Andreazza, A.C., Cassini, C., Rosa, A.R., Leite, M.C., Almeida, L.M.V., Nardin, P., Cunha, A.B.N., Cereser, K.M., Santin, A., Gottfried, C., Salvador, M., Kapczinski, F., Goncalves, C.A., Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 41:6 (2007), 523–529.
15. Andreazza, A.C., Kapczinski, F., Kauer-Sant'Anna, M., Walz, J.C., Bond, D.J., Goncalves, C.A., Young, L.T., Yatham, L.N., 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 34:4 (2009), 263–271.
16. Andreazza, A.C., Kauer-Sant'anna, M., Frey, B.N., Bond, D.J., Kapczinski, F., Young, L.T., Yatham, L.N., Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord. 111:2–3 (2008), 135–144.
17. Arenillas, J.F., Moro, M.A., Davalos, A., The metabolic syndrome and stroke: potential treatment approaches. Stroke 38:7 (2007), 2196–2203.
18. Aydemir, O., Cubukcuoglu, Z., Erdin, S., Tas, C., Onur, E., Berk, M., Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev. Bras. Psiquiatr. 36:4 (2014), 293–297.
19. Baez-Duarte, B.G., Zamora-Ginez, I., De Jesus, K.L., Torres-Rasgado, E., Gonzalez-Mejia, M.E., Porchia, L., Ruiz-Vivanco, G., Perez-Fuentes, R., Association of the metabolic syndrome with antioxidant defense and outstanding superoxide dismutase activity in Mexican subjects. Metab. Syndr. Relat. Disord. 14:3 (2016), 154–160.
20. Baldwin, W., McRae, S., Marek, G., Wymer, D., Pannu, V., Baylis, C., Johnson, R.J., Sautin, Y.Y., Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60:4 (2011), 1258–1269.
21. Baliarsingh, S., Sharma, N., Mukherjee, R., Serum uric acid: marker for atherosclerosis as it is positively associated with “atherogenic index of plasma”. Arch. Physiol. Biochem. 119:1 (2012), 27–31.
22. Baptista, T., De Mendoza, S., Beaulieu, S., Bermúdez, A., Martinez, M., The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab. Syndr. Relat. Disord. 2:4 (2004), 290–307.
23. Baptista, T., Sandia, I., Fernandez, E., Balzan, L., Connell, L., Uzcategui, E., Serrano, A., Pabon, A., Angeles, F., Araque, Y., Delgado, H., Gonzalez, A., Alviarez, Y., Piaero, J., de Baptista, E.A., Metabolic syndrome and related variables, insulin resistance, leptin levels, and PPAR-gamma2 and leptin gene polymorphisms in a pedigree of subjects with bipolar disorder. Rev. Bras. Psiquiatr. 37:2 (2015), 106–112.
24. Barandas, R., Landgraf, D., McCarthy, M.J., Welsh, D.K., Circadian clocks as modulators of metabolic comorbidity in psychiatric disorders. Curr. Psychiatr. Rep., 17(12), 2015, 98.
25. Becking, G.C., Johnson, W.J., The inhibition of tryptophan pyrrolase by allopurinol, an inhibitor of xanthine oxidase. Can. J. Biochem. 45:11 (1967), 1667–1672.
26. Belvederi Murri, M., Prestia, D., Mondelli, V., Pariante, C., Patti, S., Olivieri, B., Arzani, C., Masotti, M., Respino, M., Antonioli, M., Vassallo, L., Serafini, G., Perna, G., Pompili, M., Amore, M., The HPA axis in bipolar disorder: systematic review and meta-analysis. Psychoneuroendocrinology 63 (2016), 327–342.
27. Benton, T., Staab, J., Evans, D.L., Medical co-morbidity in depressive disorders. Ann. Clin. Psychiatry 19:4 (2007), 289–303.
28. Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yücel, M., Gama, C.S., Dodd, S., Dean, B., Magalhães, P.V., Amminger, P., McGorry, P., Malhi, G.S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35:3 (2011), 804–817.
29. Berk, M., Malhi, G.S., Gray, L.J., Dean, O.M., The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 34:3 (2013), 167–177.
30. Berk, M., Ng, F., Dean, O., Dodd, S., Bush, A.I., Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci. 29:7 (2008), 346–351.
31. Bond, D.J., Andreazza, A.C., Hughes, J., Dhanoa, T., Torres, I.J., Kozicky, J.M., Young, L.T., Lam, R.W., Yatham, L.N., Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology 65 (2015), 76–83.
32. Bonnefont-Rousselot, D., Resveratrol and cardiovascular diseases. Nutrients, 8(5), 2016, 10.3390/nu8050250 (E250 [pii]).
33. Bonomini, F., Rodella, L.F., Rezzani, R., Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis. 6:2 (2015), 109–120.
34. Bortolasci, C.C., Vargas, H.O., Souza-Nogueira, A., Gastaldello Moreira, E., Vargas Nunes, S.O., Berk, M., Dodd, S., Barbosa, D.S., Maes, M., Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. Redox Rep. 19:6 (2014), 232–241.
35. Bortolasci, C.C., Vargas, H.O., Souza-Nogueira, A., Gastaldello Moreira, E., Vargas Nunes, S.O., Berk, M., Dodd, S., Barbosa, D.S., Maes, M., Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. Redox Rep. 19:6 (2014), 232–241.
36. Bortolasci, C.C., Vargas, H.O., Vargas Nunes, S.O., de Melo, L.G., de Castro, M.R., Moreira, E.G., Dodd, S., Barbosa, D.S., Berk, M., Maes, M., Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. J. Affect. Disord. 179 (2015), 148–155.
37. Bortolato, B., Berk, M., Maes, M., RS, McIntyre, Carvalho, A.F., Fibromyalgia and bipolar disorder: emerging epidemiological associations and shared pathophysiology. Curr. Mol. Med. 16:2 (2016), 119–136.
38. Bortolato, B., Carvalho, A.F., Soczynska, J.K., Perini, G.I., McIntyre, R.S., The involvement of TNF-alpha in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr. Neuropharmacol. 13:5 (2015), 558–576.
39. Bortolato, B., Miskowiak, K.W., Kohler, C.A., Maes, M., Fernandes, B.S., Berk, M., Carvalho, A.F., Cognitive remission: a novel objective for the treatment of major depression?. BMC Med., 14, 2016, 9.
40. Boutagy, N.E., McMillan, R.P., Frisard, M.I., Hulver, M.W., Metabolic endotoxemia with obesity: is it real and is it relevant?. Biochimie 124 (2016), 11–20.
41. Bragg, D.A., Walling, A., Metabolic syndrome: hyperlipidemia. FP Essent 435 (2015), 17–23.
42. Caimi, G., Hopps, E., Montana, M., Noto, D., Canino, B., Lo Presti, R., Averna, M.R., Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. Diabet. Metab. Syndr. 6:3 (2012), 132–135.
43. Callaghan, R.C., Veldhuizen, S., Jeysingh, T., Orlan, C., Graham, C., Kakouris, G., Remington, G., Gatley, J., Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J. Psychiatr. Res. 48:1 (2014), 102–110.
44. Capuron, L., Su, S., Miller, A.H., Bremner, J.D., Goldberg, J., Vogt, G.J., Maisano, C., Jones, L., Murrah, N.V., Vaccarino, V., Depressive symptoms and metabolic syndrome: is inflammation the underlying link?. Biol. Psychiatry 64:10 (2008), 896–900.
45. Ceron, J.J., Tecles, F., Tvarijonaviciute, A., Serum paraoxonase 1 (PON1) measurement: an update. BMC Vet. Res., 10, 2014, 74.
46. Chaddha, A., Eagle, K.A., Cardiology patient page. Omega-3 fatty acids and heart health. Circulation 132:22 (2015), e350–e352.
47. Chang, T., Lung, F., Yen, Y.-C., Depressive symptoms, cognitive impairment, and metabolic syndrome in community-dwelling elderly in Southern Taiwan. Psychogeriatrics, 2014, 10.1111/psyg.12080 (1479-8301 (Electronic)).
48. Charalambous, B.M., Stephens, R.C., Feavers, I.M., Montgomery, H.E., Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28:1 (2007), 15–23.
49. Chaudhari, K., Khanzode, S., Khanzode, S., Dakhale, G., Saoji, A., Sarode, S., Clinical correlation of alteration of endogenous antioxidant-uric acid level in major depressive disorder. Indian J. Clin. Biochem. 25:1 (2010), 77–81.
50. Chen, C.C., Li, T.C., Chang, P.C., Liu, C.S., Lin, W.Y., Wu, M.T., Li, C.I., Lai, M.M., Lin, C.C., Association among cigarette smoking, metabolic syndrome, and its individual components: the metabolic syndrome study in Taiwan. Metab. Clin. Exp. 57:4 (2008), 544–548.
51. Choi, H.K., Ford, E.S., Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 120:5 (2014), 442–447.
52. Chu, N.F., Wang, D.J., Liou, S.H., Shieh, S.M., Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. Eur. J. Epidemiol. 16:1 (2000), 13–17.
53. Connell, P., Young, V.M., Toborek, M., Cohen, D.A., Barve, S., CJ, McClain, Hennig, B., Zinc attenuates tumor necrosis factor-mediated activation of transcription factors in endothelial cells. J. Am. Coll. Nutr., 1997 (0731-5724 (Print)).
54. Creta, E., Fabbri, C., Serretti, A., Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes. Pharmacogenet. Genomics 25:7 (2015), 354–362.
55. de Oliveira Otto, M.C., Alonso, A., Lee, D.H., Delclos, G.L., Bertoni, A.G., Jiang, R., Lima, J.A., Symanski, E., Jacobs, D.R. Jr., Nettleton, J.A., Dietary intakes of zinc and heme iron from red meat, but not from other sources, are associated with greater risk of metabolic syndrome and cardiovascular disease. J. Nutr. 142:3 (2012), 526–533.
56. Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., Frye, R., Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci. Biobehav. Rev. 55 (2015), 294–321.
57. Depner, C.M., Stothard, E.R., Wright, K.P. Jr., Metabolic consequences of sleep and circadian disorders. Curr. Diab. Rep., 14(7), 2014, 507.
58. Di Minno, M.N., Iervolino, S., Zincarelli, C., Lupoli, R., Ambrosino, P., Pizzicato, P., Di Minno, A., Pappone, N., Peluso, R., Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opin. Drug Saf. 14:2 (2016), 1905–1913.
59. Dik, M.G., Jonker, C., Comijs, H.C., Deeg, D.J., Kok, A., Yaffe, K., Penninx, B.W., Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 30:10 (2007), 2655–2660.
60. Dipnall, J.F., Pasco, J.A., Meyer, D., Berk, M., Williams, L.J., Dodd, S., Jacka, F.N., The association between dietary patterns, diabetes and depression. J. Affect. Disord. 174 (2015), 215–224.
61. Dixon, J.B., Hayden, M.J., Lambert, G.W., Dawood, T., Anderson, M.L., Dixon, M.E., O'Brien, P.E., Raised CRP levels in obese patients: symptoms of depression have an independent positive association. Obesity (Silver Spring) 16:9 (2008), 2010–2015.
62. Fabbrini, E., Serafini, M., Colic Baric, I., Hazen, S.L., Klein, S., Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 63:3 (2014), 976–981.
63. Facchini, F., Chen, Y.D., Hollenbeck, C.B., Reaven, G.M., Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:21 (1991), 3008–3011.
64. Fagiolini, A., Frank, E., Scott, J.A., Turkin, S., Kupfer, D.J., Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 7:5 (2005), 424–430.
65. Fearon, I.M., Faux, S.P., Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J. Mol. Cell. Cardiol. 47:3 (2009), 372–381.
66. Feng, Z., Hu, W., Marnett, L.J., Tang, M.-s., Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV- and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutat. Res. 601:1–2 (2006), 125–136.
67. Feoli, A.M., Macagnan, F.E., Piovesan, C.H., Bodanese, L.C., Siqueira, I.R., Xanthine oxidase activity is associated with risk factors for cardiovascular disease and inflammatory and oxidative status markers in metabolic syndrome: effects of a single exercise session. Oxidative Med. Cell. Longev., 2014, 2014, 587083.
68. Fernandes, B.S., Dean, O.M., Dodd, S., Malhi, G.S., Berk, M., N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J. Clin. Psychiatry 77:4 (2016), e457–e466.
69. Fries, G.R., Pfaffenseller, B., Stertz, L., Paz, A.V., Dargél, A.A., Kunz, M., Kapczinski, F., Staging and neuroprogression in bipolar disorder. Clin. Psychopharmacol. Neurosci. 14:2 (2012), 117–130.
70. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., Shimomura, I., Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114:12 (2004), 1752–1761.
71. Gałecki, P., Gałecka, E., Maes, M., Chamielec, M., Orzechowska, A., Bobińska, K., Lewiński, A., Szemraj, J., The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J. Affect. Disord. 138:3 (2012), 360–366.
72. Gałecki, P., Szemraj, J., Bieńkiewicz, M., Florkowski, A., Gałecka, E., Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Patient Educ. Couns. 61:3 (2009), 436–447.
73. Gao, C., Liu, Y., Yu, Q., Yang, Q., Li, B., Sun, L., Yan, W., Cai, X., Gao, E., Xiong, L., Wang, H., Tao, L., TNF-alpha antagonism ameliorates myocardial ischemia-reperfusion injury in mice by upregulating adiponectin. Am. J. Physiol. Heart Circ. Physiol. 308:12 (2015), H1583–H1591.
74. Gao, J., Gao, X., Pan, S., Effect of minocycline on carotid atherosclerotic plaques. Neurol. Res. 35:8 (2013), 844–850.
75. Gao, L., Mao, Q., Cao, J., Wang, Y., Zhou, X., Fan, L., Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 221:2 (2011), 311–316.
76. Garate, I., Garcia-Bueno, B., Madrigal, J.L., Caso, J.R., Alou, L., Gomez-Lus, M.L., Micó, J.A., Leza, J.C., Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol. Psychiatry 73:1 (2013), 32–43.
77. Ghasemi, A., Zahediasl, S., Azizi, F., Elevated nitric oxide metabolites are associated with obesity in women. Arch. Iran. Med. 16:9 (2013), 521–525.
78. Ghayour-Mobarhan, M., Taylor, A., Kazemi-Bajestani, S.M., Lanham-New, S., Lamb, D.J., Vaidya, N., Livingstone, C., Wang, T., Ferns, G.A., Serum zinc and copper status in dyslipidaemic patients with and without established coronary artery disease. Clin. Lab. 54:9–10 (2008), 321–329.
79. Ghosh, S., Banerjee, S., Sil, P.C., The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem. Toxicol. 83 (2015), 111–124.
80. Gibson, K.R., Winterburn, T.J., Barrett, F., Sharma, S., SM, MacRury, Megson, I.L., Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Cardiovasc. Diabetol., 10, 2011, 43.
81. Givertz, M.M., Anstrom, K.J., Redfield, M.M., Deswal, A., Haddad, H., Butler, J., Tang, W.H., Dunlap, M.E., LeWinter, M.M., Mann, D.L., Felker, G.M., O'Connor, C.M., Goldsmith, S.R., Ofili, E.O., Saltzberg, M.T., Margulies, K.B., Cappola, T.P., Konstam, M.A., Semigran, M.J., McNulty, S.E., Lee, K.L., Shah, M.R., Hernandez, A.F., Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 131:20 (2015), 1763–1771.
82. Goldsmith, D.R., Rapaport, M.H., Miller, B.J., A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry, 2016, 10.1038/mp.2016.3 (1476-5578 (Electronic)).
83. Goldstein, B.I., Carnethon, M.R., Matthews, K.A., RS, McIntyre, Miller, G.E., Raghuveer, G., Stoney, C.M., Wasiak, H., BW, McCrindle, Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. 2015 (1524-4539 (Electronic)).
84. Goldstein, B.I., Kemp, D.E., Soczynska, J.K., RS, McIntyre, Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70:8 (2009), 1078–1090.
85. Gomes, E.C., Silva, A.N., de Oliveira, M.R., Oxidants, antioxidants, and the beneficial roles of exercise-induced production of reactive species. Oxidative Med. Cell. Longev., 2012, 2012, 756132.
86. Gonen, B., Fallon, J.J., Baker, S.A., Immunogenicity of malondialdehyde-modified low density lipoproteins. Studies with monoclonal antibodies. Atherosclerosis 65:3 (1987), 265–272.
87. Goszcz, K., Deakin, S.J., Duthie, G.G., Stewart, D., Leslie, S.J., Megson, I.L., Antioxidants in cardiovascular therapy: panacea or false hope?. Front. Cardiovasc. Med., 2, 2015, 29.
88. Gougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., Yekehtaz, H., Akhondzadeh, S., Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial. J. Psychopharmacol. 29:5 (2015), 575–581.
89. Gounopoulos, P., Merki, E., Hansen, L.F., Choi, S.H., Tsimikas, S., Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 55:6 (2007), 821–837.
90. Grande, I., Magalhães, P.V., Kunz, M., Vieta, E., Kapczinski, F., Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol. Behav. 106:1 (2012), 46–50.
91. Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Gordon, D.J., Krauss, R.M., Savage, P.J., Smith, S.C. Jr., Spertus, J.A., Costa, F., American Heart Association; National Heart, Lung, and Blood Institute, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit. Pathw. Cardiol. 4:4 (2005), 198–203.
92. Guarner, V., Rubio-Ruiz, M.E., Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip. Top. Gerontol. 40 (2014), 99–106.
93. Gurbuz Ozgur, B., Aksu, H., Birincioglu, M., Dost, T., Antidepressant-like effects of the xanthine oxidase enzyme inhibitor allopurinol in rats. A comparison with fluoxetine. Pharmacol. Biochem. Behav. 138 (2015), 91–95.
94. Gustafson, B., Gogg, S., Hedjazifar, S., Jenndahl, L., Hammarstedt, A., Smith, U., Inflammation and impaired adipogenesis in hypertrophic obesity in man. 2009 (1522-1555 (Electronic)).
95. Hamalainen, P., Saltevo, J., Kautiainen, H., Mäntyselkä, P., Vanhala, M., Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovasc. Diabetol., 11, 2012, 116.
96. Han, S., Cai, W., Yang, X., Jia, Y., Zheng, Z., Wang, H., Li, J., Li, Y., Gao, J., Fan, L., Hu, D., ROS-mediated NLRP3 inflammasome activity is essential for burn-induced acute lung injury. Mediat. Inflamm., 2015, 2015, 720457.
97. Hashemian, M., Poustchi, H., Mohammadi-Nasrabadi, F., Hekmatdoost, A., Systematic review of zinc biochemical indicators and risk of coronary heart disease. 2015 1735-3955 (Print).
98. Hayes, J.D., Pulford, D.J., The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:6 (1995), 445–600.
99. He, B.M., Zhao, S.P., Peng, Z.Y., Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. J. Cell. Biochem. 114:11 (2013), 2431–2436.
100. He, B.M., Zhao, S.P., Peng, Z.Y., Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. 2013 (1097-4644 (Electronic).
101. He, Q.R., Yu, T., Li, P., Association of oxidative stress and serum adiponectin in patients with metabolic syndrome. 2009 (1672-173X (Print).
102. He, Z., Li, M., Zheng, D., Chen, Q., Liu, W., Feng, L., Adipose tissue hypoxia and low-grade inflammation: a possible mechanism for ethanol-related glucose intolerance?. Br. J. Nutr. 113:9 (2015), 1355–1364.
103. Heffner, J.L., Strawn, J.R., DelBello, M.P., Strakowski, S.M., Anthenelli, R.M., The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disord. 13:5–6 (2011), 439–453.
104. Herken, H., Gurel, A., Selek, S., Armutcu, F., Ozen, M.E., Bulut, M., Kap, O., Yumru, M., Savas, H.A., Akyol, O., Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. 2007 (0188-4409 (Print)).
105. Herva, A., Räsänen, P., Miettunen, J., Timonen, M., Läksy, K., Veijola, J., Laitinen, J., Ruokonen, A., Joukamaa, M., Co-occurrence of metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth Cohort Study. Psychosom. Med. 68:2 (2006), 213–216.
106. Hosseinzadeh-Attar, M.J., Golpaie, A., Foroughi, M., Hosseinpanah, F., Zahediasl, S., Azizi, F., The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome. J. Endocrinol. Investig. 39:8 (2016), 917–922.
107. Huang, H.C., Jan, T.R., Yeh, S.F., Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 221:2–3 (1992), 381–384.
108. Hulthe, J., Antibodies to oxidized LDL in atherosclerosis development–clinical and animal studies. Clin. Chim. Acta 348:1–2 (2004), 1–8.
109. Hutcheson, R., Rocic, P., The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. 2012 (1687-5303 (electronic)).
110. Itariu, B.K., Stulnig, T.M., Autoimmune aspects of type 2 diabetes mellitus - a mini-review. Gerontology 60:3 (2014), 189–196.
111. Jacka, F.N., Maes, M., Pasco, J.A., Williams, L.J., Berk, M., Nutrient intakes and the common mental disorders in women. J. Affect. Disord. 141:1 (2012), 79–85.
112. Jacka, F.N., Pasco, J.A., Williams, L.J., Leslie, E.R., Dodd, S., Nicholson, G.C., Kotowicz, M.A., Berk, M., Lower levels of physical activity in childhood associated with adult depression. J. Sci. Med. Sport 14:3 (2011), 222–226.
113. Jahangard, L., Soroush, S., Haghighi, M., Ghaleiha, A., Bajoghli, H., Holsboer-Trachsler, E., Brand, S., In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur. Neuropsychopharmacol. 24:8 (2014), 1210–1221.
114. Jamshidi, L., Seif, A., Vazinigheysar, H., Branch, H., Comparison of indicators of metabolic syndrome in Iranian smokers. Zahedan J. Res. Med. Sci. 16 (2014), 55–58.
115. Jankovic, A., Korac, A., Buzadzic, B., Stancic, A., Otasevic, V., Ferdinandy, P., Daiber, A., Korac, B., Targeting the nitric oxide/superoxide ratio in adipose tissue: relevance in obesity and diabetes management. Br. J. Pharmacol., 2016, 10.1111/bph.13498 (1476-5381 (Electronic)).
116. Jenner, A., Ren, M., Rajendran, R., Ning, P., Huat, B.T., Watt, F., Halliwell, B., Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic. Biol. Med. 42:4 (2007), 559–566.
117. Jequier, E., Leptin signaling, adiposity, and energy balance. Ann. N. Y. Acad. Sci. 967 (2002), 379–388 (0077-8923 (Print)).
118. Jiang, M., Qin, P., Yang, X., Comorbidity between depression and asthma via immune-inflammatory pathways: a meta-analysis. J. Affect. Disord. 166 (2014), 22–29.
119. Johnson, R.J., Nakagawa, T., Sanchez-Lozada, L.G., Shafiu, M., Sundaram, S., Le, M., Ishimoto, T., Sautin, Y.Y., Lanaspa, M.A., Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 62:10 (2013), 3307–3315.
120. Jurenka, J.S., Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev. 14:2 (2009), 141–153.
121. Kakoti, B.B., Hernandez-Ontiveros, D.G., Kataki, M.S., Shah, K., Pathak, Y., Panguluri, S.K., Resveratrol and omega-3 fatty acid: its implications in cardiovascular diseases. Front. Cardiovasc. Med., 2, 2015, 38.
122. Kametsu, Y., Kitagawa, Y., Sekiyama, S., Takagi, S., Increase in plasma malondialdehyde-modified low-density lipoprotein in patients with atherothrombotic cerebral infarction. Tokai J. Exp. Clin. Med. 30:3 (2005), 171–176.
123. Kan, C., Silva, N., Golden, S.H., Rajala, U., Timonen, M., Stahl, D., Ismail, K., A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 36:2 (2013), 480–489.
124. Karve, A.V., Jagtiani, S.S., Chitnis, K.A., Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J. Pharm. 45:3 (2013), 244–247.
125. Keane, K.N., Cruzat, V.F., Carlessi, R., de Bittencourt, P.I. Jr., Newsholme, P., Molecular events linking oxidative stress and inflammation to insulin resistance and beta-cell dysfunction. Oxidative Med. Cell. Longev., 2015, 2015, 181643.
126. Kemp, D.E., Gao, K., Chan, P.K., Ganocy, S.J., Findling, R.L., Calabrese, J.R., Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 12:4 (2010), 404–413.
127. Khanzode, S.D., Dakhale, G.N., Khanzode, S.S., Saoji, A., Palasodkar, R., Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 8:6 (2003), 365–370.
128. Khosravi-Boroujeni, H., Ahmed, F., Sadeghi, M., Roohafza, H., Talaei, M., Dianatkhah, M., Pourmogaddas, A., Sarrafzadegan, N., Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions?. BMC Public Health, 15, 2015, 1313.
129. Kikuchi, K., Uchikado, H., Morioka, M., Murai, Y., Tanaka, E., Clinical neuroprotective drugs for treatment and prevention of stroke. Int. J. Mol. Sci. 13:6 (2012), 7739–7761.
130. Kim, J.I., Huh, J.Y., Sohn, J.H., Choe, S.S., Lee, Y.S., Lim, C.Y., Jo, A., Park, S.B., Han, W., Kim, J.B., Lipid-overloaded enlarged adipocytes provoke insulin resistance independent of inflammation. Mol. Cell. Biol. 35:10 (2015), 1686–1699.
131. Kim, Y.K., Paik, J.W., Lee, S.W., Yoon, D., Han, C., Lee, B.H., Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30:6 (2006), 1091–1096.
132. Kinder, L.S., Carnethon, M.R., Palaniappan, L.P., King, A.C., Fortmann, S.P., Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom. Med. 66:3 (2004), 316–322.
133. Kohler, O., Gasse, C., Petersen, L., Ingstrup, K.G., Nierenberg, A.A., Mors, O., Ostergaard, S.D., The effect of concomitant treatment with SSRIs and statins: a population-based study. Am. J. Psychiatry 173:8 (2016), 807–815.
134. Konrad, D., Wueest, S., The gut-adipose-liver axis in the metabolic syndrome. Physiology (Bethesda) 29:5 (2014), 304–313.
135. Kraakman, M.J., Kammoun, H.L., Allen, T.L., Deswaerte, V., Henstridge, D.C., Estevez, E., Matthews, V.B., Neill, B., White, D.A., Murphy, A.J., Peijs, L., Yang, C., Risis, S., Bruce, C.R., Du, X.J., Bobik, A., Lee-Young, R.S., Kingwell, B.A., Vasanthakumar, A., Shi, W., Kallies, A., Lancaster, G.I., Rose-John, S., Febbraio, M.A., Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 21:3 (2015), 403–416.
136. Kulkarni, S., Dhir, A., Akula, K.K., Potentials of curcumin as an antidepressant. Sci. World J. 9 (2009), 1233–1241.
137. Kuno, A., Tanno, M., Horio, Y., The effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy. Ann. N. Y. Acad. Sci. 1348:1 (2015), 46–54.
138. Kupfer, D.J., The increasing medical burden in bipolar disorder. JAMA 293:20 (2005), 2528–2530.
139. Laakso, M., Kuusisto, J., Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10:5 (2014), 293–302.
140. Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., Salonen, J.T., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:21 (2002), 2709–2716.
141. Lanaspa, M.A., Sanchez-Lozada, L.G., Choi, Y.-J., Cicerchi, C., Kanbay, M., Roncal-Jimenez, C.A., Ishimoto, T., Li, N., Marek, G., Duranay, M., Schreiner, G., Rodriguez-Iturbe, B., Nakagawa, T., Kang, D.-H., Sautin, Y.Y., Johnson, R.J., Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J. Biol. Chem. 287:48 (2012), 40732–40744.
142. Lasser, K., Boyd, J.W., Woolhandler, S., Himmelstein, D.U., McCormick, D., Bor, D.H., Smoking and mental illness: a population-based prevalence study. JAMA 284:20 (2000), 2606–2610.
143. Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., Kupfer, D.J., Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect. Disord. 141:1 (2012), 1–10.
144. Lee, K.U., Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res. Clin. Pract. 54:Suppl. 2 (2001), S29–S33.
145. Lee, S.R., Noh, S.J., Pronto, J.R., Jeong, Y.J., Kim, H.K., Song, I.S., Xu, Z., Kwon, H.Y., Kang, S.C., Sohn, E.H., Ko, K.S., Rhee, B.D., Kim, N., Han, J., The critical roles of zinc: beyond impact on myocardial signaling. Korean J. Physiol. Pharmacol. 19:5 (2015), 389–399.
146. Lemche, E., Chaban, O.S., Lemche, A.V., Neuroendorine and Epigentic mechanisms Subserving autonomic imbalance and HPA dysfunction in the metabolic syndrome. Front. Neurosci., 10, 2016.
147. Leo, R., Di Lorenzo, G., Tesauro, M., Cola, C., Fortuna, E., Zanasi, M., Troisi, A., Siracusano, A., Lauro, R., Romeo, F., Decreased plasma adiponectin concentration in major depression. Neurosci. Lett. 407:3 (2006), 211–213.
148. Leonard, B., Maes, M., Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 36:2 (2012), 764–785.
149. Lett, H.S., Blumenthal, J.A., Babyak, M.A., Sherwood, A., Strauman, T., Robins, C., Newman, M.F., Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom. Med. 66:3 (2004), 305–315.
150. Liao, T.V., Forehand, C.C., Hess, D.C., Fagan, S.C., Minocycline repurposing in critical illness: focus on stroke. Curr. Top. Med. Chem. 13:18 (2013), 2283–2290.
151. Libert, S., Pointer, K., Bell, E.L., Das, A., Cohen, D.E., Asara, J.M., Kapur, K., Bergmann, S., Preisig, M., Otowa, T., Kendler, K.S., Chen, X., Hettema, J.M., van den Oord, E.J., Rubio, J.P., Guarente, L., SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive. Cell 147:7 (2011), 1459–1472.
152. Lin, P.Y., Su, K.P., A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 68:7 (2007), 1056–1061.
153. Lin, S.D., Tsai, D.H., Hsu, S.-R., Association between serum uric acid level and components of the metabolic syndrome. J. Diabet. Metab. Disord., 14, 2006, 70.
154. Linsel-Nitschke, P., Tall, A.R., HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4:3 (2005), 193–205.
155. Lippi, G., Montagnana, M., Luca Salvagno, G., Targher, G., Cesare Guidi, G., Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile. Clin. Cardiol. 33:2 (2010), E76–E80.
156. Litvinova, L., Atochin, D.N., Fattakhov, N., Vasilenko, M., Zatolokin, P., Kirienkova, E., Nitric oxide and mitochondria in metabolic syndrome. Front. Physiol., 6, 2015, 20.
157. Liu, C.S., Carvalho, A.F., Mansur, R.B., RS, McIntyre, Obesity and bipolar disorder: synergistic neurotoxic effects?. Adv. Ther. 30:11 (2013), 987–1006.
158. Liu, C.S., Carvalho, A.F., McIntyre, R.S., Towards a “metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol. Disord. Drug Targets 13:10 (2014), 1693–1707.
159. Liu, S., Li, T., Liu, H., Wang, X., Bo, S., Xie, Y., Bai, X., Wu, L., Wang, Z., Liu, D., Resveratrol exerts antidepressant properties in the chronic unpredictable mild stress model through the regulation of oxidative stress and mTOR pathway in the rat hippocampus and prefrontal cortex. Behav. Brain Res. 302 (2016), 191–199.
160. Lomb, D.J., Laurent, G., Haigis, M.C., Sirtuins regulate key aspects of lipid metabolism. Biochim. Biophys. Acta 1804:8 (2010), 1652–1657.
161. Lucas, K., Morris, G., Anderson, G., Maes, M., The Toll-like receptor radical cycle pathway: a new drug target in immune-related chronic fatigue. CNS Neurol. Disord. Drug Targets 14:7 (2015), 838–854.
162. Lucas, K., Maes, M., Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. 2013 (1559-1182 (electronic)).
163. Lucas, K., Maes, M., Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol. Neurobiol. 48:1 (2013), 190–204.
164. Mabuchi, H., Nohara, A., Kobayashi, J., Kawashiri, M.-a., Katsuda, S., Inazu, A., Koizumi, J., Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 195:2 (2007), e182–e189.
165. Mabuchi, H., Nohara, A., Kobayashi, J., Kawashiri, M.-A., Katsuda, S., Inazu, A., Koizumi, J., Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. 2007 (1879-1484 (Electronic)).
166. Machado-Vieira, R., Soares, J.C., Lara, D.R., Luckenbaugh, D.A., Busnello, J.V., Marca, G., Cunha, A., Souza, D.O., Zarate, C.A. Jr., Kapczinski, F., A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry 69:8 (2008), 1237–1245.
167. Maes, M., The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett. 29:3 (2008), 287–291.
168. Maes, M., Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr.t Opin. Psychiatry 22:1 (2009), 75–83.
169. Maes, M., Delanghe, J., Scharpe, S., Meltzer, H.Y., Cosyns, P., Suy, E., Bosmans, E., Haptoglobin phenotypes and gene frequencies in unipolar major depression. Am. J. Psychiatry 151:1 (1994), 112–116.
170. Maes, M., Kubera, M., Leunis, J.C., Berk, M., Geffard, M., Bosmans, E., In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr. Scand. 127:5 (2013), 344–354.
171. Maes, M., Kubera, M., Mihaylova, I., Geffard, M., Galecki, P., Leunis, J.C., Berk, M., Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J. Affect. Disord. 149:1–3 (2013), 23–29.
172. Maes, M., Kubera, M., Obuchowiczwa, E., Goehler, L., Brzeszcz, J., Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol. Lett. 32:1 (2011), 7–24.
173. Maes, M., Leonard, B., Fernandez, A., Kubera, M., Nowak, G., Veerhuis, R., Gardner, A., Ruckoanich, P., Geffard, M., Altamura, C., Galecki, P., Berk, M., (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:3 (2011), 659–663.
174. Maes, M., Libbrecht, I., Van Hunsel, F., Lin, A.H., De Clerck, L., Stevens, W., Kenis, G., de Jongh, R., Bosmans, E., Neels, H., The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 24:4 (1999), 371–383.
175. Maes, M., Lin, A., Bonaccorso, S., van Hunsel, F., Van Gastel, A., Delmeire, L., Biondi, M., Bosmans, E., Kenis, G., Scharpe, S., Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr. Scand. 98:4 (1998), 328–335.
176. Maes, M., Lin, A.H., Delmeire, L., Van Gastel, A., Kenis, G., De Jongh, R., Bosmans, E., Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol. Psychiatry 45:7 (1999), 833–839.
177. Maes, M., Lin, A.H., Verkerk, R., Delmeire, L., Van Gastel, A., Van der Planken, M., Scharpe, S., Serotonergic and noradrenergic markers of post-traumatic stress disorder with and without major depression. Neuropsychopharmacology 20:2 (1999), 188–197.
178. Maes, M., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N., Bosmans, E., Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J. Affect. Disord. 125:1–3 (2010), 287–294.
179. Maes, M., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N., Bosmans, E., Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol. Lett. 32:2 (2011), 133–140.
180. Maes, M., Ruckoanich, P., Chang, Y.S., Mahanonda, N., Berk, M., Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:3 (2011), 769–783.
181. Maes, M., Ruckoanich, P., Chang, Y.S., Mahanonda, N., Berk, M., Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:3 (2011), 769–783.
182. Maes, M., Smith, R., Christophe, A., Vandoolaeghe, E., Van Gastel, A., Neels, H., Demedts, P., Wauters, A., Meltzer, H.Y., Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr. Scand. 95:3 (1997), 212–221.
183. Maes, M., Smith, R., Scharpe, S., The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 20:2 (1995), 111–116.
184. Maes, M., Song, C., Lin, A.H., Pioli, R., Kenis, G., Kubera, M., Bosmans, E., In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology 143:4 (1999), 401–407.
185. Maes, M., Song, C., Yirmiya, R., Targeting IL-1 in depression. Expert Opin. Ther. Targets 16:11 (2012), 1097–1112.
186. Maes, M., Vandeweghe, M., Du Caju, M., Ernould, C., Bourguignon, J.P., Massa, G., A valuable improvement of adult height prediction methods in short normal children. Horm. Res. 48:4 (1997), 184–190.
187. Maes, M., Vandewoude, M., Scharpe, S., De Clercq, L., Stevens, W., Lepoutre, L., Schotte, C., Anthropometric and biochemical assessment of the nutritional state in depression: evidence for lower visceral protein plasma levels in depression. J. Affect. Disord. 23:1 (1991), 25–33.
188. Maes, M.B., Scharpe, S., De Meester, I., Dipeptidyl peptidase II (DPPII), a review. Clin. Chim. Acta 380:1–2 (2007), 31–49.
189. Mallick, S., D'Mello, S.R., JAZ (Znf346), a SIRT1-interacting protein, protects neurons by stimulating p21 (WAF/CIP1) protein expression. J. Biol. Chem. 289:51 (2014), 35409–35420.
190. Mandal, K., Jahangiri, M., Xu, Q., Autoimmune mechanisms of atherosclerosis. Handb. Exp. Pharmacol. 170 (2005), 723–743.
191. Mansego, M.L., Solar Gde, M., Alonso, M.P., Martínez, F., Sáez, G.T., Escudero, J.C., Redón, J., Chaves, F.J., Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J. Hypertens. 29:3 (2011), 492–500.
192. Mansur, R.B., Brietzke, E., McIntyre, R.S., Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci. Biobehav. Rev. 52 (2015), 89–104.
193. Mansur, R.B., Rizzo, L.B., Santos, C.M., Asevedo, E., Cunha, G.R., Noto, M.N., Pedrini, M., Zeni, M., Cordeiro, Q., McIntyre, R.S., Brietzke, E., Adipokines, metabolic dysfunction and illness course in bipolar disorder. J. Psychiatr. Res. 74 (2016), 63–69.
194. Marchetti, G., Lodola, E., Licciardello, L., Colombo, A., Use of N-acetylcysteine in the management of coronary artery diseases. Cardiologia 44:7 (1999), 633–637.
195. Martin-Subero, M., Anderson, G., Kanchanatawan, B., Berk, M., Maes, M., Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr. 21:2 (2016), 184–198.
196. Martina, V., Masha, A., Gigliardi, V.R., Brocato, L., Manzato, E., Berchio, A., Massarenti, P., Settanni, F., Della Casa, L., Bergamini, S., Iannone, A., Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 31:5 (2008), 940–944.
197. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:7 (1985), 412–419.
198. McEachin, R.C., Saccone, N.L., Saccone, S.F., Kleyman-Smith, Y.D., Kar, T., Kare, R.K., Ade, A.S., Sartor, M.A., Cavalcoli, J.D., McInnis, M.G., Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder. BMC Med. Genet., 11, 2010, 14.
199. McElroy, S.L., Keck, P.E. Jr., Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J. Clin. Psychiatry 75:1 (2014), 46–61.
200. McIntyre, R.S., Alsuwaidan, M., Goldstein, B.I., Taylor, V.H., Schaffer, A., Beaulieu, S., Kemp, D.E., The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann. Clin. Psychiatry 24:1 (2012), 69–81.
201. McIntyre, R.S., Park, K.Y., Law, C.W., Sultan, F., Adams, A., Lourenco, M.T., Lo, A.K., Soczynska, J.K., Woldeyohannes, H., Alsuwaidan, M., Yoon, J., Kennedy, S.H., The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 24:9 (2010), 741–753.
202. McIntyre, R.S., Rasgon, N.L., Kemp, D.E., Nguyen, H.T., Law, C.W., Taylor, V.H., Woldeyohannes, H.O., Alsuwaidan, M.T., Soczynska, J.K., Kim, B., Lourenco, M.T., Kahn, L.S., Goldstein, B.I., Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr. Diabet. Rep. 9:1 (2012), 51–59.
203. Meerarani, P., Ramadass, P., Toborek, M., Bauer, H.C., Bauer, H., Hennig, B., Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor alpha. 2000 (0002-9165 (Print)).
204. Meng, X., Ao, L., Song, Y., Babu, A., Yang, X., Wang, M., Weyant, M.J., Dinarello, C.A., Cleveland, J.C. Jr., Fullerton, D.A., Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am. J. Phys. Cell Physiol. 294:1 (2008), C29–C35.
205. Menon, A.S., Kotwal, N., Singh, Y., Girish, R., Statins: cholesterol guidelines and Indian perspective. Indian J. Endocrinol. Metab. 19:5 (2015), 546–553.
206. Michel, T.M., Frangou, S., Thiemeyer, D., Camara, S., Jecel, J., Nara, K., Brunklaus, A., Zoechling, R., Riederer, P., Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder–a postmortem study. Psychiatry Res. 151:1–2 (2007), 145–150.
207. Milaneschi, Y., Lamers, F., Bot, M., Drent, M.L., Penninx, B.W., Leptin dysregulation is specifically associated with major depression with atypical features: evidence for a mechanism connecting obesity and depression. Biol. Psychiatry, 2015 (1873-2402 (Electronic)).
208. Millan, J., Pinto, X., Munoz, A., Zuniga, M., Rubies-Prat, J., Pallardo, L.F., Masana, L., Mangas, A., Hernandez-Mijares, A., Gonzalez-Santos, P., Ascaso, J.F., Pedro-Botet, J., Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc. Health Risk Manag. 5 (2009), 757–765.
209. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65:9 (2009), 732–741.
210. Miyake, T., Kumagi, T., Furukawa, S., Hirooka, M., Kawasaki, K., Koizumi, M., Todo, Y., Yamamoto, S., Abe, M., Kitai, K., Matsuura, B., Hiasa, Y., Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One, 9(9), 2014, e107882.
211. Mokdad, A.H., Ford, E.S., Bowman, B.A., Dietz, W.H., Vinicor, F., Bales, V.S., Marks, J.S., Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J. Affect. Disord. 289:1 (2003), 76–79.
212. Molina-Hernandez, M., Téllez-Alcántara, N.P., Pérez-García, J., Olivera-Lopez, J.I., Jaramillo-Jaimes, M.T., Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32:7 (2008), 1660–1666.
213. Moreno-Indias, I., Oliva-Olivera, W., Omiste, A., Castellano-Castillo, D., Lhamyani, S., Camargo, A., Tinahones, F.J., Adipose tissue infiltration in normal-weight subjects and its impact on metabolic function. Transl. Res. 172 (2016), 6–17 S1931-5244(16)00021-9 [pii] 10.1016/j.trsl.2016.01.002.
214. Morris, G., Anderson, G., Berk, M., Maes, M., Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol. Neurobiol. 48:3 (2013), 883–903.
215. Morris, G., Berk, M., The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med., 13, 2015, 68.
216. Morris, G., Berk, M., Galecki, P., Walder, K., Maes, M., The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. 2016 (1559-1182 (Electronic)).
217. Morris, K.C., Lin, H.W., Thompson, J.W., Perez-Pinzon, M.A., Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J. Cereb. Blood Flow Metab. 31:4 (2011), 1003–1019.
218. Mortuza, R., Chen, S., Feng, B., Sen, S., Chakrabarti, S., High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One, 8(1), 2013, e54514.
219. Motawi, T.K., Darwish, H.A., Hamed, M.A., El-Rigal, N.S., Naser, A.F., A therapeutic insight of niacin and coenzyme Q10 against diabetic encephalopathy in rats. Mol. Neurobiol., 2016 (1559-1182 (Electronic)).
220. Moylan, S., Berk, M., Dean, O.M., Samuni, Y., Williams, L.J., O'Neil, A., Hayley, A.C., Pasco, J.A., Anderson, G., Jacka, F.N., Maes, M., Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav. Rev. 45:0 (2014), 46–62.
221. Moylan, S., Maes, M., Wray, N.R., Berk, M., The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 18:5 (2013), 595–606.
222. Muraca, M., Putignani, L., Fierabracci, A., Teti, A., Perilongo, G., Gut microbiota-derived outer membrane vesicles: under-recognized major players in health and disease?. Discov. Med. 19:106 (2015), 343–348.
223. Murphy, J.M., Monson, R.R., Olivier, D.C., Sobol, A.M., Leighton, A.H., Affective disorders and mortality. A general population study. Arch. Gen. Psychiatry 44:5 (1987), 473–480.
224. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98:1–2 (2006), 143–151.
225. Nasr, G., Maurice, C., Allopurinol and global left myocardial function in heart failure patients. J. Cardiovasc. Dis. Res. 1:4 (2010), 191–195.
226. Naumova, A.V., Chacko, V.P., Ouwerkerk, R., Stull, L., Marban, E., Weiss, R.G., Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 290:2 (2005), H837–H843.
227. Nicolaides, N.C., Charmandari, E., Chrousos, G.P., Kino, T., Circadian endocrine rhythms: the hypothalamic-pituitary-adrenal axis and its actions. Ann. N. Y. Acad. Sci. 1318 (2014), 71–80.
228. Nowak, G., Szewczyk, B., Pilc, A., Zinc and depression. An update. Pharmacol. Rep. 57:6 (2005), 713–718.
229. Nunes, S.O., Vargas, H.O., Prado, E., Barbosa, D.S., de Melo, L.P., Moylan, S., Dodd, S., Berk, M., The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci. Biobehav. Rev. 37:8 (2013), 1336–1345.
230. Nunes, S.O.V., de Castro, Márcia Regina Pizzo, Vargasa, Heber Odebrecht, Vargas, Mateus Mendonça, de Batista Fonseca, Inês Cristina, Dodd, Seetal, Berk, Michael, Clinical characteristics and smoking cessation: an analysis of sex and depressive disorders differences. Addict. Disord. Treat. 12:3 (2013), 158–165.
231. Nunes, S.O.V., de Melo, L.G.P., de Castro, M.R.P., Barbosa, D.S., Vargas, H.O., Berk, M., Maes, M., Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J. Affect. Disord., 0, 2015.
232. Nunes, S.O.V., Vargas, H.O., Prado, E., Barbosa, D.S., de Melo, L.P., Moylan, S., Dodd, S., Berk, M., The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci. Biobehav. Rev. 37:8 (2013), 1336–1345.
233. Ogino, K., Kato, M., Furuse, Y., Kinugasa, Y., Ishida, K., Osaki, S., Kinugawa, T., Igawa, O., Hisatome, I., Shigemasa, C., Anker, S.D., Doehner, W., Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ. Heart Fail. 3:1 (2010), 73–81.
234. Onat, A., Uyarel, H., Hergenc, G., Karabulut, A., Albayrak, S., Sari, I., Yazici, M., Keles, I., Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am. J. Hypertens. 19:10 (2006), 1055–1062.
235. Onyedum, C.C., Young, E.E., Iroezindu, M.O., Chukwuka, C.J., Nwagha, U.I., Atherogenic index of plasma in highly active antiretroviral therapy-naive patients with human immunodeficiency virus infection in Southeast Nigeria. Indian J. Endocrinol. Metab. 18:5 (2014), 631–636.
236. Orozco-Solis, R., Sassone-Corsi, P., Epigenetic control and the circadian clock: linking metabolism to neuronal responses. Neuroscience 264 (2014), 76–87.
237. Parikh, N.I., Gerschenson, M., Bennett, K., Gangcuangco, L.M., Lopez, M.S., Mehta, N.N., Playford, M.P., Nakamoto, B.K., Seto, T.B., Chow, D.C., Shikuma, C.M., Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort. Atherosclerosis 239:1 (2014), 50–54.
238. Pasco, J.A., Jacka, F.N., Williams, L.J., Henry, M.J., Nicholson, G.C., Kotowicz, M.A., Berk, M., Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J. Affect. Disord. 107:1–3 (2008), 221–225.
239. Pavlov, V.A., Tracey, K.J., The vagus nerve and the inflammatory reflex–linking immunity and metabolism. Nat. Rev. Endocrinol. 8:12 (2012), 743–754.
240. Pei, H., Song, X., Peng, C., Tan, Y., Li, Y., Li, X., Ma, S., Wang, Q., Huang, R., Yang, D., Li, D., Gao, E., Yang, Y., TNF-alpha inhibitor protects against myocardial ischemia/reperfusion injury via Notch1-mediated suppression of oxidative/nitrative stress. Free Radic. Biol. Med. 82 (2015), 114–121.
241. Pena, C.J., Bagot, R.C., Labonte, B., Nestler, E.J., Epigenetic signaling in psychiatric disorders. Dialogues Clin. Neurosci. 16:3 (2014), 281–295.
242. Pizzo de Castro, M.R., Vargas Nunes, S.O., Guembarovski, R.L., Ariza, C.B., Oda, J.M., Vargas, H.O., Piccoli de Melo, L.G., Watanabe, M.A., Berk, M., Maes, M., STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. J. Affect. Disord. 172 (2015), 347–354.
243. Raftery, G., He, J., Pearce, R., Birchall, D., Newton, J.L., Blamire, A.M., Isaacs, J.D., Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Res. Ther., 14(6), 2012, R263.
244. Raj, P., Zieroth, S., Netticadan, T., An overview of the efficacy of resveratrol in the management of ischemic heart disease. Ann. N. Y. Acad. Sci. 1348:1 (2015), 55–67.
245. Rani, V., Deep, G., Singh, R.K., Palle, K., Yadav, U.C., Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 148 (2016), 183–193.
246. Redlich, C., Berk, M., Williams, L.J., Sundquist, J., Sundquist, K., Li, X., Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatr., 14, 2014, 348.
247. Robillard, R., Naismith, S.L., Hickie, I.B., Recent advances in sleep-wake cycle and biological rhythms in bipolar disorder. Curr. Psychiatr. Rep., 15(10), 2013, 402.
248. Roncal-Jimenez, C.A., Lanaspa, M.A., Rivard, C.J., Nakagawa, T., Sanchez-Lozada, L.G., Jalal, D., Andres-Hernando, A., Tanabe, K., Madero, M., Li, N., Cicerchi, C., Mc Fann, K., Sautin, Y.Y., Johnson, R.J., Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake. Metab. Clin. Exp. 60:9 (2014), 1259–1270.
249. Ryo, M., Nakamura, T., Kihara, S., Kumada, M., Shibazaki, S., Takahashi, M., Nagai, M., Matsuzawa, Y., Funahashi, T., Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 68:11 (2004), 975–981.
250. Salagre, E., Fernandes, B.S., Dodd, S., Brownstein, D.J., Berk, M., Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J. Affect. Disord. 200 (2016), 235–242.
251. Sandek, A., Rauchhaus, M., Anker, S.D., von Haehling, S., The emerging role of the gut in chronic heart failure. Curr. Opin. Clin. Nutr. Metab. Care 11:5 (2008), 632–639.
252. Sankhla, M., Sharma, T.K., Mathur, K., Rathor, J.S., Butolia, V., Gadhok, A.K., Vardey, S.K., Sinha, M., Kaushik, G.G., Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin. Lab. 58:5–6 (2012), 385–392.
253. Sautin, Y.Y., Johnson, R.J., Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27:6 (2008), 608–619.
254. Senti, M., Tomás, M., Fitó, M., Weinbrenner, T., Covas, M.I., Sala, J., Masiá, R., Marrugat, J., Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88:11 (2003), 5422–5426.
255. Shen, H., Oesterling, E., Stromberg, A., Toborek, M., MacDonald, R., Hennig, B., Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling. J. Am. Acad. Child Adolesc. Psychiatry 27:5 (2008), 577–587.
256. Shi, J., Zhang, X., Wang, S., Wang, J., Du, B., Wang, Z., Liu, M., Jiang, W., Qian, M., Ren, H., Gpr97 is dispensable for metabolic syndrome but is involved in macrophage inflammation in high-fat diet-induced obesity in mice. Sci. Rep., 19, 2016, 24649.
257. Siervo, M., Harrison, S.L., Jagger, C., Robinson, L., Stephan, B.C., Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. J. Alzheimers Dis. 41:1 (2014), 151–161.
258. Skilton, M.R., Moulin, P., Terra, J.-L., Bonnet, F., Associations between anxiety, depression, and the metabolic syndrome. Biol. Psychiatry 62:11 (2007), 1251–1257.
259. Solomon, C.G., Manson, J.E., Obesity and mortality: a review of the epidemiologic data. Am. J. Clin. Nutr. 66:4 Suppl (1997), 1044S–1050S.
260. Song, C., Wang, H., Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:3 (2011), 760–768.
261. Song, J., Kim, J., Role of Sirtuins in linking metabolic syndrome with depression. Front. Cell. Neurosci., 10, 2016, 86.
262. Srivastava, R., Dikshit, M., Srimal, R.C., Dhawan, B.N., Anti-thrombotic effect of curcumin. Thromb. Res. Nov. 1:3 (1985), 413–417.
263. Steinerova, A., Racek, J., Stozický, F., Zima, T., Fialová, L., Lapin, A., Antibodies against oxidized LDL–theory and clinical use. Physiol. Res. 50:2 (2001), 131–141.
264. Stetler, C., Miller, G.E., Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 73:2 (2011), 114–126.
265. Stull, L.B., Leppo, M.K., Szweda, L., Gao, W.D., Marban, E., Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ. Res. 95:10 (2004), 1005–1011.
266. Szewczyk, B., Kubera, M., Nowak, G., The role of zinc in neurodegenerative inflammatory pathways in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:3 (2011), 693–701.
267. Takata, K., Imaizumi, S., Kawachi, E., Suematsu, Y., Shimizu, T., Abe, S., Matsuo, Y., Tsukahara, H., Noda, K., Yahiro, E., Zhang, B., Uehara, Y., Miura, S., Saku, K., Impact of cigarette smoking cessation on high-density lipoprotein functionality. Circ. J. 78:12 (2014), 2955–2962.
268. Talarowska, M., Berk, M., Maes, M., Galecki, P., Autobiographical memory dysfunctions in depressive disorders. Psychiatry Clin. Neurosci. 70:2 (2016), 100–108.
269. Talarowska, M., Gałecki, P., Maes, M., Orzechowska, A., Chamielec, M., Bartosz, G., Kowalczyk, E., Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci. Lett. 510:2 (2012), 127–131.
270. Thomas, C., Hypponen, E., Power, C., Obesity and type 2 diabetes risk in midadult life: the role of childhood adversity. Pediatrics 121:5 (2008), e1240–e1249.
271. Toalson, P., Ahmed, S., Hardy, T., Kabinoff, G., The metabolic syndrome in patients with severe mental illnesses. Prim. Care Companion J. Clin. Psychiatry 6:4 (2004), 152–158.
272. Trevino, S., Aguilar-Alonso, P., Flores Hernandez, J.A., Brambila, E., Guevara, J., Flores, G., Lopez-Lopez, G., Munoz-Arenas, G., Morales-Medina, J.C., Toxqui, V., Venegas, B., Diaz, A., A high calorie diet causes memory loss, metabolic syndrome and oxidative stress into hippocampus and temporal cortex of rats. Synapse 69:9 (2015), 421–433.
273. Treweeke, A.T., Winterburn, T.J., Mackenzie, I., Barrett, F., Barr, C., Rushworth, G.F., Dransfield, I., SM, MacRury, Megson, I.L., N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Diabetologia 55:11 (2012), 2920–2928.
274. Tu, K.Y., Wu, M.K., Chen, Y.-W., Lin, P.-Y., Wang, H.-Y., Wu, C.-K., Tseng, P.-T., Significantly higher peripheral insulin-like growth factor-1 levels in patients with major depressive disorder or bipolar disorder than in healthy controls: a meta-analysis and review under guideline of PRISMA. Medicine (Baltimore), 95(4), 2016, e2411.
275. Tucsek, Z., Toth, P., Sosnowska, D., Gautam, T., Mitschelen, M., Koller, A., Szalai, G., Sonntag, W.E., Ungvari, Z., Csiszar, A., Obesity in aging exacerbates blood-brain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer's disease. J. Gerontol. A Biol. Sci. Med. Sci. 69:10 (2013), 1212–1226.
276. Tuttolomondo, A., Pecoraro, R., Pinto, A., Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des. Devel. Ther. 8 (2014), 2221–2238.
277. Vaarala, O., Antibodies to oxidised LDL. Lupus 9:3 (2000), 202–205.
278. Valkanova, V., Ebmeier, K.P., Allan, C.L., CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 150:3 (2013), 736–744.
279. Vancampfort, D., Correll, C.U., Wampers, M., Sienaert, P., Mitchell, A.J., De Herdt, A., Probst, M., Scheewe, T.W., De Hert, M., Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol. Med. 44:10 (2013), 2017–2028.
280. Vancampfort, D., Stubbs, B., Mitchell, A.J., De Hert, M., Wampers, M., Ward, P.B., Rosenbaum, S., Correll, C.U., Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14:3 (2015), 339–347.
281. Vancampfort, D., Vansteelandt, K., Correll, C.U., Mitchell, A.J., De Herdt, A., Sienaert, P., Probst, M., De Hert, M., Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 170:3 (2013), 265–274.
282. Vancampfort, D., Vansteelandt, K., Correll, C.U., Mitchell, A.J., De Herdt, A., Sienaert, P., Probst, M., De Hert, M., Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 170:3 (2013), 265–274.
283. Vargas, H.O., Nunes, S.O., Barbosa, D.S., Vargas, M.M., Cestari, A., Dodd, S., Venugopal, K., Maes, M., Berk, M., Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sci. 102:1 (2014), 65–71.
284. Vargas, H.O., Nunes, S.O., de Castro, M.R., Vargas, M.M., Barbosa, D.S., Bortolasci, C.C., Venugopal, K., Dodd, S., Berk, M., Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neurosci. Lett. 544 (2013), 136–140.
285. Vargas, H.O., Nunes, S.O., Pizzo de Castro, M., Cristina Bortolasci, C., Sabbatini Barbosa, D., Kaminami Morimoto, H., Venugopal, K., Dodd, S., Maes, M., Berk, M., Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J. Affect. Disord. 150:3 (2013), 923–930.
286. Vargas, H.O., Nunes, S.O.V., Barbosa, D.S., Vargas, M.M., Cestari, A., Dodd, S., Venugopal, K., Maes, M., Berk, M., Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sci. 102:1 (2014), 65–71.
287. Venkatesan, N., Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br. J. Pharmacol. 124:3 (1998), 425–427.
288. Venturini, D., Simao, A.N., Scripes, N.A., Bahls, L.D., Melo, P.A.S., Belinetti, F.M., Lozovoy, M.A.B., Dichi, I., Evaluation of oxidative stress in overweight subjects with or without metabolic syndrome. Obesity (Silver Spring) 20:12 (2012), 2361–2366.
289. Viscogliosi, G., Andreozzi, P., Chiriac, I.M., Cipriani, E., Servello, A., Marigliano, B., Ettorre, E., Marigliano, V., Depressive symptoms in older people with metabolic syndrome: is there a relationship with inflammation?. Int. J. Geriatr. Psychiatry 28:3 (2013), 242–247.
290. Viscogliosi, G., Chiriac, I.M., Andreozzi, P., Ettorre, E., The metabolic syndrome predicts longitudinal changes in clock drawing test performance in older nondemented hypertensive individuals. Am. J. Geriatr. Psychiatry 24:5 (2016), 359–363.
291. Vlaicu, S.I., Tatomir, A., Boodhoo, D., Vesa, S., Mircea, P.A., Rus, H., The role of complement system in adipose tissue-related inflammation. Immunol. Res. 64:3 (2016), 653–664.
292. Vogelzangs, N., Beekman, A.T., Boelhouwer, I.G., Bandinelli, S., Milaneschi, Y., Ferrucci, L., Penninx, B.W., Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons. J. Clin. Psychiatry 72:5 (2011), 598–604.
293. Volt, H., Garcia, J.A., Doerrier, C., Diaz-Casado, M.E., Guerra-Librero, A., Lopez, L.C., Escames, G., Tresguerres, J.A., Acuna-Castroviejo, D., Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin. J. Pineal Res. 60:2 (2016), 193–205.
294. Walker, E.R., McGee, R.E., Druss, B.G., Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72:4 (2015), 334–341.
295. Wan, X., Xu, C., Lin, Y., Lu, C., Li, D., Sang, J., He, H., Liu, X., Li, Y., Yu, C., Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J. Hepatol. 64:4 (2016), 925–932.
296. Wang, Q.Y., Sun, P., Zhang, Q., Yao, S.L., Minocycline attenuates microglial response and reduces neuronal death after cardiac arrest and cardiopulmonary resuscitation in mice. J. Huazhong Univ. Sci. Technol. Med. Sci. 35:2 (2015), 225–229.
297. Weiser, M., Burshtein, S., Gershon, A.A., Marian, G., Vlad, N., Grecu, I.G., Tocari, E., Tiugan, A., Hotineanu, M., Davis, J.M., Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord. 16:4 (2014), 441–447.
298. Wen, S., Cheng, M., Wang, H., Yue, J., Wang, H., Li, G., Zheng, L., Zhong, Z., Peng, F., Serum uric acid levels and the clinical characteristics of depression. Clin. Biochem. 45:1–2 (2012), 49–53.
299. WHO, Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser. 894:i-xii (2000), 1–253.
300. WHO, Diet, nutrition and the prevention of chronic diseases. World Health Organ. Tech. Rep. Ser. 797 (2003), 1–204.
301. Williams, L.J., Pasco, J.A., Henry, M.J., Jacka, F.N., Dodd, S., Nicholson, G.C., Kotowicz, M.A., Berk, M., Lifetime psychiatric disorders and body composition: a population-based study. J. Affect. Disord. 118:1–3 (2009), 173–179.
302. Wium-Andersen, M.K., Orsted, D.D., Nordestgaard, B.G., Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. Br. J. Psychiatry 208:2 (2016), 138–145.
303. Wongcharoen, W., Phrommintikul, A., The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 133:2 (2009), 145–151.
304. Wysokinski, A., Strzelecki, D., Kloszewska, I., Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabet. Metab. Syndr. 9:3 (2015), 168–176.
305. Yang, Y.K., Wang, L.P., Chen, L., Yao, X.P., Yang, K.Q., Gao, L.G., Zhou, X.L., Coenzyme Q10 treatment of cardiovascular disorders of ageing including heart failure, hypertension and endothelial dysfunction. Clin. Chim. Acta 450 (2015), 83–89.
306. Yates, K.F., Sweat, V., Yau, P.L., Turchiano, M.M., Convit, A., Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler. Thromb. Vasc. Biol. 32:9 (2012), 2060–2067.
307. Ye, J., Liu, Z., Wei, J., Lu, L., Huang, Y., Luo, L., Xie, H., Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neurosci. Lett. 553 (2013), 72–77.
308. Zang, Q., Maass, D.L., Tsai, S.J., Horton, J.W., Cardiac mitochondrial damage and inflammation responses in sepsis. Surg. Infect. 8:1 (2007), 41–54.
309. Zhang, C., Zhang, D.F., Wu, Z.G., Peng, D.H., Chen, J., Ni, J., Tang, W., Xu, L., Yao, Y.G., Fang, Y.R., Complement factor H and susceptibility to major depressive disorder in Han Chinese. Br. J. Psychiatry 208:5 (2016), 446–452.